Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Conditioned Medium for Diabetes Mellitus
jRCT1051250139Recruiting
- Sponsor
- Tokyo Showa Clinic
- Start
- Oct 2025
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in diabetes mellitus (DM), sponsored by Tokyo Showa Clinic. Primary endpoints: Condition of the patient, Blood sugar level and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on jRCT1051250139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250139.